CD38 and Miyoshi myopathy: While we adopted the 3D model that is published by Kirshner et al. [12], we employed a different approach to estimate the number of viable MM cells by combining both flow cytometric analysis of CD38+ percentage and trypan blue staining of viable bone marrow mononuclear cells.